InsidersTradesSigma
셀트리온 Stock: price and directors' dealings · South Korea · DART (FSS)
Follow the 셀트리온 stock price and the full insider trade history of the company, a publicly traded company based in South Korea. Shares are listed on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 셀트리온 has recorded 460 insider filings. Market capitalisation: €40,361.6bn. The latest transaction was reported on 7 July 2026 (Other). Among the most active insiders: 셀트리온홀딩스. Every trade is accessible without an account.
460
Insider Decl.
0
Thresholds
€17m
41 ops.
Buy Volume
€68m
53 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 셀트리온 Buy (bullish), based on 24 analysts. Average price target: ₩255,593.
Fundamental score
Ranked 13,788 of 25,821 companies
50.0
score / 100
Value35
Quality66
FCF yld0.8%
Earn yld2.5%
EV/EBITDA29.4x
ROE7.3%
Gross mgn59%
Net mgn25%
Debt/EBITDA2.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 7 July 2026
Declarations460 total
25 of 460 declarations
About 셀트리온
Celltrion is a South Korean company focused on the development and manufacturing of biosimilar drugs and innovative therapies. It is listed on the Korea Exchange, XKRX.